Literature DB >> 12118899

Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve.

Elias David-Neto1, Lilian M P Araujo, Zita M L Brito, Cristiane F Alves, Francine C Lemos, Elisa M Yagyu, William C Nahas, Luiz E Ianhez.   

Abstract

The complete area under the time-concentration curve (AUC) is considered to be the gold standard for cyclosporin-A (CyA) monitoring. However, complete AUC is time- and cost-consuming. For this reason, we reviewed 259 4-h AUC (AUC0-4) performed in 74 renal transplanted patients in order to construct an equation to calculate AUC0-4. All samples were drawn from one adult population 13 days following transplantation, in order to allow the cyclosporin metabolism to stabilize. Regression analysis was done either with each or with a combination of two variables. Cyclosporin-A blood concentration at the second hour after the oral dose (C2) was the best predictor of AUC0-4, where AUC0-4 = 451 +(2.73 x C2), R2 = 0.87, p<0.001. The combination of C1 and C2 only, offered a better mathematical improvement to the C2 equation. This equation was further validated in 33 other CyA pharmacokinetic profiles performed in eight patients who had not participated in the equation development. In this new population, the C2 equation excellently predicted the trapezoidal AUC0-4 (R2 = 0.81). Our data shows that C2 can be safely used to estimate AUC0-4. The C2 equation simplifies CyA monitoring because of its high-predictive value and clinical feasibility.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118899     DOI: 10.1034/j.1600-6143.2002.20609.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  4 in total

1.  Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients.

Authors:  Hui Zhou; Yan Gao; Xiao-Liang Cheng; Zhong-Dong Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-03-25       Impact factor: 2.441

2.  Calcineurin inhibitors exacerbate coronary arteritis via the MyD88 signalling pathway in a murine model of Kawasaki disease.

Authors:  K Murata; Y Motomura; T Tanaka; S Kanno; T Yano; M Onimaru; A Shimoyama; H Nishio; Y Sakai; M Oh-Hora; H Hara; K Fukase; H Takada; S Masuda; S Ohga; S Yamasaki; T Hara
Journal:  Clin Exp Immunol       Date:  2017-07-21       Impact factor: 4.330

3.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.

Authors:  Kenji Ishikura; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Yoshitsugu Kaku; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.617

4.  Current best practice management of interstitial cystitis/bladder pain syndrome.

Authors:  Esther Han; Laura Nguyen; Larry Sirls; Kenneth Peters
Journal:  Ther Adv Urol       Date:  2018-03-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.